• Paloma Martín-Jiménez, Laura Bermejo-Guerrero, Ana Hernandez-Voth, Ana Arteche-López, Aurelio Hernández-Lain, María Rabasa, and Cristina Domínguez-González.
• Unidad de Enfermedades Neuromusculares, Servicio de Neurología, Hospital Universitario 12 de Octubre, Madrid, España.
• Med Clin (Barc). 2024 Aug 17.

IntroductionPompe Disease (PD) is a lysosomal disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA), primarily manifesting as a progressive myopathy with early respiratory involvement. Enzyme replacement therapy (ERT) is available since 2006.Materials And MethodsWe describe 13 patients with partial GAA deficiency, followed at Hospital 12 de Octubre, 8 of whom were receiving treatment.Results8 patients exhibit symptoms, all with late onset. They display axial and proximal weakness predominantly in the lower limbs but maintain autonomous gait. Five patients require non-invasive mechanical ventilation due to respiratory insufficiency. All symptomatic patients receive ERT, and in 7/8 (87.5%), there is a decline in motor and pulmonary function after an average of 8.25 years of treatment (baseline and post-treatment FVC and 6MWT mean 86.6% vs 70.8% and 498 vs 430 meters, respectively).ConclusionNot all patients with partial GAA deficiency experience symptoms of PD, and symptomatic patients, despite ERT with recombinant alpha-glucosidase, mostly experience a gradual decline in motor and respiratory function.Copyright © 2024 Elsevier España, S.L.U. All rights reserved.

10 keywords...

hide…